China vs the US: what actually differs for patients

Key takeaways

• New-patient specialist waits in the US averaged 31 days across five specialties in 2025, up from 26 days in 2022 [1].
• US billing has three different numbers — charge, negotiated rate and what you pay — which is why a single headline price means little [5].
• In one US health system, a thoracic surgeon doing more than 25 lung resections a year counted as high-volume [2]. A two-surgeon group at Shanghai Chest Hospital reported 1,434 operations in 2024 [3].
• Volume and outcome are linked in the published literature, which is the honest version of “Chinese surgeons operate more” [4].
• New drugs usually reach China later, but Hainan's Boao Lecheng zone lets designated hospitals use overseas-approved products that are not yet registered in China [7][8].

The comparison, in one table

1. Waiting: slow where it is not urgent

The most-quoted American number comes from a survey of physician offices in 15 metropolitan areas. In 2025 it found an average wait of 31 days for a new-patient appointment across cardiology, dermatology, obstetrics and gynaecology, orthopaedic surgery and family medicine — 19% longer than the 26 days recorded in 2022 [1].

Three limits belong in the same paragraph as the number. It measures new-patient office appointments, not how long you wait for an operation. It covers five specialties, not oncology or neurosurgery. And it measures the non-urgent pathway: emergencies, heart attacks and strokes move on a completely different track.

China's side needs the same discipline. An international department can see you within days, but the CT slot and the operating list still depend on how busy that department is. The question worth asking is not “how long do you wait” but:

“From the decision to operate to the day of the operation, what is the average wait in this department?” That number exists. Ask for it, and ask whether it is measured in days or weeks.

2. Money: two systems, three numbers each

A US hospital bill carries a charge that almost nobody pays, a negotiated rate that insurers pay, and an out-of-pocket figure that you pay. Those three numbers can differ several-fold for the same operation [5]. That is why “what does a hip replacement cost in America” has no single answer, and why any comparison built on one headline figure should be read with suspicion.

China has its own two-tier structure. The ordinary clinic is priced against a government fee schedule. The international or premium department prices independently, sits outside Chinese medical insurance, and is capped at roughly 10% of a hospital's volume; reported multiples run 3–10 times the insured rate, higher for surgery than for tests [6].

The comparison that means something is same condition, same operation, same tier of service. We break the payment mechanics down separately in Paying for care in China, including why fewer than 30% of international insurers can settle directly.

3. Volume: what Chinese surgeons actually do

This is the claim most often made and least often documented, so here are the actual figures on both sides.

China, institution level. Shanghai Chest Hospital publishes an annual cardiothoracic surgical volume of more than 23,000 operations, and more recent recruitment material puts it above 32,000, with 90% or more of them major or complex cases. Its lung surgery division alone reports more than 18,000 operations a year, and its robotic thoracic programme passed 9,500 cumulative cases, which the hospital describes as the highest in China [3].

China, surgeon level. One two-surgeon group in that department published its 2024 summary: 1,434 operations in a year — about 1,000 lung resections, 65 oesophageal, 125 mediastinal, 170 chest-wall corrections — with no perioperative deaths and two unplanned returns to theatre [3].

United States. A study across an eight-hospital health system defined thoracic surgeons doing more than 25 lung resections a year as high-volume, and found that this group had better value outcomes [2]. Nationally, the Society of Thoracic Surgeons database recorded 13,336 lobectomies in 2022 across all participating centres [4].

Read the definitions before reading the gap. The 25 figure counts lung resections only; the 1,434 counts all thoracic operations. They cannot be divided into a clean multiple, and we do not present them that way. What can be said without overreach is that a group doing 1,000 lung operations a year is operating at a frequency that the American high-volume threshold does not anticipate.

Why frequency matters. A systematic review and meta-analysis of lung cancer resection found that procedure volume and surgeon specialty were associated with postoperative mortality and long-term survival [4]. The mechanism is not mysterious: recognising a bleeding vessel, deciding when a staple line is safe, spotting the early signs of a leak — these are learned on the table, at volume, or not at all.

And the limit. Volume is a property of the team and the institution, not a guarantee about the person holding the instrument. So the question to ask is never “how many does this hospital do” but:

“How many of this operation does my surgeon do each year?” A centre that cannot answer that question about a named surgeon has a marketing problem, not a volume problem.

4. Drugs: China lags, and Hainan is the exception

New medicines generally reach China after the United States, with delays that vary enormously between products and therapeutic areas. For a patient whose remaining options are drugs approved abroad but not yet in China, that gap is the whole story.

Hainan's Boao Lecheng pilot zone is the exception. Under the clinically-urgent import policy, designated hospitals there may use drugs and devices that are approved overseas but not yet registered in China.

The last row matters more than its size suggests. Until this year that insurance pool covered Chinese residents only; the 2026 edition opened it to foreign nationals living in China, which is the first time this particular payment route has been available to them.

Boundaries to state plainly: Lecheng is special-permission use, not routine care. The list is finite, eligibility depends on indication and approval, everything happens in Hainan rather than in Beijing or Shanghai, and the cost normally falls on you or your insurer.

5. Language, coordination and the parts nobody prices

There are two routes into a Chinese hospital. The international department handles registration and billing separately, usually in English, and holds direct-billing contracts with a limited set of insurers. A coordination agency such as Wellward China handles record translation, appointments, accompaniment, cost estimates and the discharge paperwork your insurer will demand.

The first is cheaper; the second is calmer. Either way, one rule should be absolute: the pre-operative conversation has to happen in a language you can confirm you understood. Signing a Chinese consent form you cannot read is not consent in any useful sense.

The condition in context: how outcomes are actually counted

Every comparison on this page is a comparison about a condition, not about a country. A hospital that is excellent at lung resection may be ordinary at pancreatic surgery, and the reverse. That is why the useful unit of comparison is a single operation with a defined risk profile, measured over a defined period.

Three numbers are worth asking for, and they are not the same: mortality (usually reported at 30 or 90 days), major complication rate (leak, reoperation, prolonged ventilation), and oncological adequacy where cancer is involved (margin status, lymph nodes sampled). A centre that reports one but not the others is choosing its metric.

Risk adjustment matters too. A department that takes on more complex cases will look worse on raw numbers than one that declines them. So when you compare two centres, ask whether the figures are risk-adjusted, and over what period they were collected.

6. When not to come

This section is the reason to trust the rest of the page.

Decision checklist

Availability and limits

• This is an editorial comparison of published figures, not medical advice about your case [1][2].
• The US waiting-time figure comes from a survey of physician offices, not from administrative data [1].
• Volume figures describe one institution and one surgical group; they are not national averages for China [3].
• The definitional gap between “25 lung resections” and “1,434 operations” is real and is not converted into a multiple here [2][3].
• Hainan access depends on product, indication and approval, and changes with the list [7][8].
• We are not a provider and do not book treatment; where we are named, it is as an example of the coordination route, not a recommendation.

What to ask before booking

Questions patients ask